Core Viewpoint - 博瑞医药 has abruptly withdrawn its plan for a private placement of A-shares for 2024, citing current market conditions and company circumstances as reasons for the decision [2] Group 1: Company Actions - The company initially planned to raise 500 million yuan through a private placement led by its actual controller, Yuan Jiandong, which was approved by the board and shareholders in May 2024 [2] - After a year of no progress on the private placement, the company revised its issuance plan multiple times before ultimately retracting the application [2][3] Group 2: Stock Price Fluctuations - 博瑞医药's stock price experienced significant volatility, rising from around 30 yuan to approximately 120 yuan within a month starting July 11, before plummeting back to 55.31 yuan [3] - The stock's dramatic rise and fall over three months has been likened to a "roller coaster" [3] Group 3: Financial Performance - The company's financial performance has deteriorated sharply, with net profit dropping by 84% to just over 17 million yuan in the first half of 2025 [4] - Revenue figures show a consistent decline, with total revenue for 2024 projected at 1.283 billion yuan, down from 1.180 billion yuan in 2023 [5] - The company reported a decline in net profit from 2022 onwards, with a significant drop in growth rates, indicating a troubling trend in profitability [5] Group 4: Company Background - 博瑞医药 is described as an innovative pharmaceutical company focused on research and development, aiming to establish a robust business model that integrates both generic and innovative drugs [5] - The company has undergone multiple rounds of financing since its IPO in 2019, including convertible bonds and a private placement, but faced regulatory scrutiny due to issues with fund management [6]

Core Viewpoint - 博瑞医药 has abruptly withdrawn its plan for a private placement of A-shares for 2024, citing current market conditions and company circumstances as reasons for this decision [2] Group 1: Company Actions - The company initially planned to raise 500 million yuan through a private placement led by its actual controller, Yuan Jiandong, but the plan faced delays and was ultimately retracted [2] - The private placement was first approved in May 2024, but after a year of no progress, the company revised the issuance plan multiple times before withdrawing it entirely [2][3] Group 2: Stock Price Fluctuations - 博瑞医药's stock price has experienced significant volatility, rising from around 30 yuan to a peak of approximately 120 yuan within a month, before plummeting back to 55.31 yuan [3] - The stock's dramatic rise and fall can be attributed to market trends and the hype surrounding innovative drug concepts [3] Group 3: Financial Performance - The company's financial performance has deteriorated sharply, with net profit dropping by 84% to approximately 17 million yuan in the first half of 2025 [6] - Historical data shows that while revenue grew steadily from 5.03 billion yuan in 2019 to 12.83 billion yuan in 2024, net profit has seen a decline since 2022, indicating a troubling trend [7] Group 4: Company Profile - 博瑞医药 is characterized as an innovative pharmaceutical company focused on research and development, specializing in complex generics and original drugs, with a dual market strategy targeting both domestic and international markets [8] - The company has undergone multiple rounds of financing since its IPO in 2019, but faced regulatory scrutiny due to issues in fund management earlier this year [8]

Core Viewpoint - The company plans to invest up to RMB 10 million in the Suzhou Rongxin Health Industry Venture Capital Center (Limited Partnership), focusing on innovative pharmaceutical products and technologies, which aligns with its main business [1][2]. Investment Overview - The investment aims to leverage the expertise of professional investment institutions to identify early-stage investment opportunities in high-potential areas such as innovative pharmaceuticals and complex formulations [2]. - The company will not guarantee minimum returns or exit guarantees for other investors in the fund [2]. Fund Management - The fund will be managed by Suzhou Rongshi Private Equity Fund Management Co., Ltd., which has a registered capital of RMB 10 million and manages funds ranging from RMB 1 billion to 2 billion [3]. - The fund is currently in the preparation and fundraising stage, with other partners yet to be fully determined [4]. Agreement and Compliance - As of the announcement date, the partnership agreement has not been signed, and the specifics will be determined by the final agreement [4]. - The investment does not constitute a related party transaction or a major asset restructuring as per regulatory definitions [2]. Financial Impact - The investment will not be consolidated into the company's financial statements and will not impose financial pressure on the company's existing operations [4]. - The funding source for the investment is the company's own funds, ensuring that normal business operations remain unaffected [4]. Risk Analysis - The investment process carries uncertainties, including the potential failure to raise sufficient funds due to partners not fulfilling their capital commitments [5]. - The company, as a limited partner, will have limited control over the fund's investment risks and will enhance communication with partners to monitor fund operations [5].